Spots Global Cancer Trial Database for Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Official Title: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients: a Collaborative Janssen - IFM Study IFM 2023-01: TEC-CARE
Study ID: NCT06062537
Conditions
Interventions
Study Description
Brief Summary: 200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed. Primary objective is the evaluation of overall response rate (ORR) of teclistamab according to IMWG criteria. This is a multicenter, prospective, observational study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CH d'ANNECY, Annecy, , France
Hopital de la cote Basque, Bayonne, , France
CHU Bordeaux, Bordeaux, , France
CHU CAEN, Caen, , France
Chu Dijon, Dijon, , France
CH Dunkerque, Dunkerque, , France
CHU de Lille, Lille, , France
CHU de Lyon, Lyon, , France
Institut Paoli Calmette, Marseille, , France
CH de METZ, Metz, , France
Chu de Nantes, Nantes, , France
CHU de Nice, Nice, , France
Hopital Necker, Paris, , France
Hopital saint louis, Paris, , France
CH Perpignan, Perpignan, , France
Hopital Novo, Pontoise, , France
Chu de Rennes, Rennes, , France
CHU Toulouse, Toulouse, , France
CHU de Tours, Tours, , France
CH Bretagne Atlantique, Vannes, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
